Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
The Clinical Development of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension
